Financhill
Sell
29

WST Quote, Financials, Valuation and Earnings

Last price:
$205.41
Seasonality move :
2.45%
Day range:
$206.26 - $209.26
52-week range:
$187.43 - $352.33
Dividend yield:
0.4%
P/E ratio:
32.73x
P/S ratio:
5.28x
P/B ratio:
5.58x
Volume:
447.4K
Avg. volume:
866.6K
1-year change:
-37.63%
Market cap:
$15B
Revenue:
$2.9B
EPS (TTM):
$6.37

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
WST
West Pharmaceutical Services
$687.4M $1.26 3.28% -0.47% $281.92
BAX
Baxter International
$2.6B $0.48 -25.95% 590.29% $38.68
PDEX
Pro-Dex
$17.7M $0.47 23.84% 147.37% $54.00
TFX
Teleflex
$699.4M $2.88 2.91% 98.97% $157.62
TMCI
Treace Medical Concepts
$52.1M -$0.30 5.9% -21.86% $9.73
UFPT
UFP Technologies
$139.9M $2.01 37.56% 28.57% $311.00
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
WST
West Pharmaceutical Services
$208.49 $281.92 $15B 32.73x $0.21 0.4% 5.28x
BAX
Baxter International
$30.27 $38.68 $15.5B 167.20x $0.17 3.04% 1.30x
PDEX
Pro-Dex
$45.62 $54.00 $148.8M 16.35x $0.00 0% 2.39x
TFX
Teleflex
$120.94 $157.62 $5.3B 38.15x $0.34 1.13% 1.88x
TMCI
Treace Medical Concepts
$6.10 $9.73 $383.7M -- $0.00 0% 1.80x
UFPT
UFP Technologies
$233.68 $311.00 $1.8B 28.60x $0.00 0% 3.32x
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
WST
West Pharmaceutical Services
7.02% 0.860 1.26% 1.80x
BAX
Baxter International
58.72% 0.052 57.45% 1.13x
PDEX
Pro-Dex
34.14% 0.505 11.31% 1.41x
TFX
Teleflex
31.78% 0.827 30.89% 1.11x
TMCI
Treace Medical Concepts
33.65% 3.967 10.12% 3.23x
UFPT
UFP Technologies
33.63% 3.826 11.76% 1.39x
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
WST
West Pharmaceutical Services
$231.9M $127.6M 16.23% 17.47% 15.89% $58.1M
BAX
Baxter International
$861M $58M -2.78% -7.38% 2.97% -$315M
PDEX
Pro-Dex
$5.8M $3.6M 20.23% 29.31% 27.56% $574K
TFX
Teleflex
$389.4M $130.3M 2.43% 3.41% 18.2% $43.1M
TMCI
Treace Medical Concepts
$41.9M -$15.6M -32% -47.17% -27.79% $655K
UFPT
UFP Technologies
$42.2M $23.4M 13.85% 19.38% 15.59% $11M

West Pharmaceutical Services vs. Competitors

  • Which has Higher Returns WST or BAX?

    Baxter International has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 4.8%. West Pharmaceutical Services's return on equity of 17.47% beat Baxter International's return on equity of -7.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    33.22% $1.23 $2.9B
    BAX
    Baxter International
    32.8% $0.25 $17.1B
  • What do Analysts Say About WST or BAX?

    West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 35.22%. On the other hand Baxter International has an analysts' consensus of $38.68 which suggests that it could grow by 27.78%. Given that West Pharmaceutical Services has higher upside potential than Baxter International, analysts believe West Pharmaceutical Services is more attractive than Baxter International.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    10 1 0
    BAX
    Baxter International
    4 11 1
  • Is WST or BAX More Risky?

    West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison Baxter International has a beta of 0.628, suggesting its less volatile than the S&P 500 by 37.167%.

  • Which is a Better Dividend Stock WST or BAX?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.4%. Baxter International offers a yield of 3.04% to investors and pays a quarterly dividend of $0.17 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Baxter International pays out -90.91% of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or BAX?

    West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Baxter International quarterly revenues of $2.6B. West Pharmaceutical Services's net income of $89.8M is lower than Baxter International's net income of $126M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 32.73x while Baxter International's PE ratio is 167.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.28x versus 1.30x for Baxter International. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.28x 32.73x $698M $89.8M
    BAX
    Baxter International
    1.30x 167.20x $2.6B $126M
  • Which has Higher Returns WST or PDEX?

    Pro-Dex has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 18.81%. West Pharmaceutical Services's return on equity of 17.47% beat Pro-Dex's return on equity of 29.31%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    33.22% $1.23 $2.9B
    PDEX
    Pro-Dex
    33.3% $0.98 $53.6M
  • What do Analysts Say About WST or PDEX?

    West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 35.22%. On the other hand Pro-Dex has an analysts' consensus of $54.00 which suggests that it could grow by 18.37%. Given that West Pharmaceutical Services has higher upside potential than Pro-Dex, analysts believe West Pharmaceutical Services is more attractive than Pro-Dex.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    10 1 0
    PDEX
    Pro-Dex
    1 0 0
  • Is WST or PDEX More Risky?

    West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison Pro-Dex has a beta of 0.365, suggesting its less volatile than the S&P 500 by 63.531%.

  • Which is a Better Dividend Stock WST or PDEX?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.4%. Pro-Dex offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Pro-Dex pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or PDEX?

    West Pharmaceutical Services quarterly revenues are $698M, which are larger than Pro-Dex quarterly revenues of $17.4M. West Pharmaceutical Services's net income of $89.8M is higher than Pro-Dex's net income of $3.3M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 32.73x while Pro-Dex's PE ratio is 16.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.28x versus 2.39x for Pro-Dex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.28x 32.73x $698M $89.8M
    PDEX
    Pro-Dex
    2.39x 16.35x $17.4M $3.3M
  • Which has Higher Returns WST or TFX?

    Teleflex has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 13.56%. West Pharmaceutical Services's return on equity of 17.47% beat Teleflex's return on equity of 3.41%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    33.22% $1.23 $2.9B
    TFX
    Teleflex
    55.58% $2.07 $6B
  • What do Analysts Say About WST or TFX?

    West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 35.22%. On the other hand Teleflex has an analysts' consensus of $157.62 which suggests that it could grow by 30.33%. Given that West Pharmaceutical Services has higher upside potential than Teleflex, analysts believe West Pharmaceutical Services is more attractive than Teleflex.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    10 1 0
    TFX
    Teleflex
    0 11 0
  • Is WST or TFX More Risky?

    West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison Teleflex has a beta of 1.170, suggesting its more volatile than the S&P 500 by 17.034%.

  • Which is a Better Dividend Stock WST or TFX?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.4%. Teleflex offers a yield of 1.13% to investors and pays a quarterly dividend of $0.34 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Teleflex pays out 91.2% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or TFX?

    West Pharmaceutical Services quarterly revenues are $698M, which are smaller than Teleflex quarterly revenues of $700.7M. West Pharmaceutical Services's net income of $89.8M is lower than Teleflex's net income of $95M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 32.73x while Teleflex's PE ratio is 38.15x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.28x versus 1.88x for Teleflex. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.28x 32.73x $698M $89.8M
    TFX
    Teleflex
    1.88x 38.15x $700.7M $95M
  • Which has Higher Returns WST or TMCI?

    Treace Medical Concepts has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of -30.29%. West Pharmaceutical Services's return on equity of 17.47% beat Treace Medical Concepts's return on equity of -47.17%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    33.22% $1.23 $2.9B
    TMCI
    Treace Medical Concepts
    79.69% -$0.25 $158.8M
  • What do Analysts Say About WST or TMCI?

    West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 35.22%. On the other hand Treace Medical Concepts has an analysts' consensus of $9.73 which suggests that it could grow by 59.49%. Given that Treace Medical Concepts has higher upside potential than West Pharmaceutical Services, analysts believe Treace Medical Concepts is more attractive than West Pharmaceutical Services.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    10 1 0
    TMCI
    Treace Medical Concepts
    2 5 0
  • Is WST or TMCI More Risky?

    West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison Treace Medical Concepts has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

  • Which is a Better Dividend Stock WST or TMCI?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.4%. Treace Medical Concepts offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. Treace Medical Concepts pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or TMCI?

    West Pharmaceutical Services quarterly revenues are $698M, which are larger than Treace Medical Concepts quarterly revenues of $52.6M. West Pharmaceutical Services's net income of $89.8M is higher than Treace Medical Concepts's net income of -$15.9M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 32.73x while Treace Medical Concepts's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.28x versus 1.80x for Treace Medical Concepts. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.28x 32.73x $698M $89.8M
    TMCI
    Treace Medical Concepts
    1.80x -- $52.6M -$15.9M
  • Which has Higher Returns WST or UFPT?

    UFP Technologies has a net margin of 12.87% compared to West Pharmaceutical Services's net margin of 11.6%. West Pharmaceutical Services's return on equity of 17.47% beat UFP Technologies's return on equity of 19.38%.

    Company Gross Margin Earnings Per Share Invested Capital
    WST
    West Pharmaceutical Services
    33.22% $1.23 $2.9B
    UFPT
    UFP Technologies
    28.45% $2.21 $543.4M
  • What do Analysts Say About WST or UFPT?

    West Pharmaceutical Services has a consensus price target of $281.92, signalling upside risk potential of 35.22%. On the other hand UFP Technologies has an analysts' consensus of $311.00 which suggests that it could grow by 33.09%. Given that West Pharmaceutical Services has higher upside potential than UFP Technologies, analysts believe West Pharmaceutical Services is more attractive than UFP Technologies.

    Company Buy Ratings Hold Ratings Sell Ratings
    WST
    West Pharmaceutical Services
    10 1 0
    UFPT
    UFP Technologies
    1 2 0
  • Is WST or UFPT More Risky?

    West Pharmaceutical Services has a beta of 1.143, which suggesting that the stock is 14.255% more volatile than S&P 500. In comparison UFP Technologies has a beta of 1.100, suggesting its more volatile than the S&P 500 by 9.979%.

  • Which is a Better Dividend Stock WST or UFPT?

    West Pharmaceutical Services has a quarterly dividend of $0.21 per share corresponding to a yield of 0.4%. UFP Technologies offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. West Pharmaceutical Services pays 12% of its earnings as a dividend. UFP Technologies pays out -- of its earnings as a dividend. West Pharmaceutical Services's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

  • Which has Better Financial Ratios WST or UFPT?

    West Pharmaceutical Services quarterly revenues are $698M, which are larger than UFP Technologies quarterly revenues of $148.1M. West Pharmaceutical Services's net income of $89.8M is higher than UFP Technologies's net income of $17.2M. Notably, West Pharmaceutical Services's price-to-earnings ratio is 32.73x while UFP Technologies's PE ratio is 28.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for West Pharmaceutical Services is 5.28x versus 3.32x for UFP Technologies. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    WST
    West Pharmaceutical Services
    5.28x 32.73x $698M $89.8M
    UFPT
    UFP Technologies
    3.32x 28.60x $148.1M $17.2M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

Will DigitalOcean Stock Bounce Back?
Will DigitalOcean Stock Bounce Back?

DigitalOcean (NYSE:DOCN) has run into the proverbial brick wall with…

Where Will Cognizant Stock Be In 5 Years?
Where Will Cognizant Stock Be In 5 Years?

Cognizant Technologies (NASDAQ:CTSH) is a global provider of IT services…

NVIDIA vs Broadcom Stock: Which Is Best?
NVIDIA vs Broadcom Stock: Which Is Best?

NVIDIA (NASDAQ:NVDA) and Broadcom (NASDAQ:AVGO) are two of the hottest…

Stock Ideas

Buy
68
Is MSFT Stock a Buy?

Market Cap: $3.4T
P/E Ratio: 39x

Buy
66
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 45x

Sell
39
Is AAPL Stock a Buy?

Market Cap: $3T
P/E Ratio: 33x

Alerts

Buy
54
AAP alert for May 23

Advance Auto Parts [AAP] is down 0.98% over the past day.

Buy
67
IONQ alert for May 23

IonQ [IONQ] is down 0.48% over the past day.

Buy
75
URBN alert for May 23

Urban Outfitters [URBN] is down 1.24% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock